🚨 ENZARAD (ANZUP 1303): 2 years of enzalutamide did not improve metastasis-free survival when added to RT + ADT in high-risk/locally advanced #prostatecancer 🚨
@JCO_ASCO
👥 802 pts, high-risk localized or locally advanced PCa (incl cN1)
📊 Open-label phase 3 RCT, definitive prostate RT + 24 mo ADT
💊 Enzalutamide 160mg daily x24 mo vs older NSAA x6 mo
⏱️ Median f/u 92 mo
✅ 8-yr MFS on conventional imaging 74% vs 72%, HR 0.88 (0.67-1.15), P=0.34, not significant
✅ No OS benefit
✅ Prespecified subgroup w/ planned pelvic nodal RT (n=324): HR 0.47 (0.29-0.76), Padj=0.004
⚠️ Subgroup signal is hypothesis-generating; grade 3-5 AEs 46% in both arms
🎯 Enzalutamide on top of RT + 2 yr ADT did not improve outcomes overall, potential signal with pelvic nodal RT subgroup
🔗 doi.org/10.1200/JCO-26-01794@urotoday@UrologyTimes@PCF_Science@SbrtSean@ChrisSweens1@Prof_IanD@UroOnc@SUO_YUO
This is an important release in @JCO_ASCO in conjunction with #ESMO26#DASL HiCaP trial. Identifying pts who benefit the most from intensified treatment is a work in progress. @ASCO@myESMO@ChrisSweens1#ENZARAD@Prof_IanD et al. @OncoAlert
ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer | Journal of Clinical Oncology ascopubs.org/doi/pdf/10.1200…
1/n Major congrats to our DASL team, especially to @ChrisSweens1 and @niazi_Dr7, and a big thanks to the patients. Working with @ANZUPtrials and @ThePCCTC on DASL as US lead has been a career highlight.
I'd contend this establishes a new standard of care in DASL very-high risk PCa. The conventional-image defined MFS benefit with the addition of Darolutamide to RT+ADT was extraordinarily robust; the DSMC recommended reporting out at IA. #ESMO26, #radonc, #medtwitter. @MSKCancerCenter@MSK_RadOnc. #pcsm
Brief 🧵
Darolutamide with ADT and locoregional
radiation therapy (RT) in high-risk prostate cancer (DASL) showed Darolutamide reduced the risk of relapse and time to CRPC. Tolerably was good. It’s imporant to identity which patients benefit, as mortality is low, and whether latest staging with PSMA-PET changes things #ESMO26@Silke_Gillessen@ChrisSweens1
Rather a brilliant discussion at the presidential #ESMO26 for the DASL very high risk prostate cancer trial
The future is patient selection. The clearest indication is in pateints with N1 disease supported by results from thr other trials @OncoAlert@ChrisSweens1@Uromigos
Genomic classifiers are shifting mHSPC treatment decisions from one-size-fits-all to evidence-based selection. I find the ENZAMET analysis a strong example of how validated assays can inform which patients truly benefit from docetaxel.